CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure Positive recommendation for angiotensin receptor/neprilysin inhibitor: First medication approval for heart failure without "reduced ejection fraction" Clinical trial design and rationale of the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) investigational device exemption clinical study protocol Frailty Is Intertwined With Heart Failure: Mechanisms, Prevalence, Prognosis, Assessment, and Management How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) Ambulatory Inotrope Infusions in Advanced Heart Failure - A Systematic Review and Meta-Analysis When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease Sex Differences in Heart Failure With Preserved Ejection Fraction Pathophysiology: A Detailed Invasive Hemodynamic and Echocardiographic Analysis

JOURNAL: Article Link

经皮冠状动脉介入治疗后的积极降脂治疗--目标人群以及如何开展?

作者:Zhen-Vin Lee等 译者:左广峰 审校:姜潇

摘要

尽管经皮冠状动脉介入治疗 (PCI) 对阻塞性冠状动脉疾病的疗效是确切的,但考虑到非手术相关的其他重要危险因素的控制程度,尚不能确保长期预后。动脉粥样硬化作为血脂异常的结果,其发展导致的风险具有连续性,因此对接受PCI的患者采取二级预防措施,对于降低手术失败以及心血管事件的风险尤为重要。本综述通过总结最新临床指南推荐,强调三种主流降脂疗法相关理论和证据(即他汀类药物、依折麦布和前蛋白转化酶枯草杆菌蛋白酶/ kexin 9型(PCSK9)抑制剂),概述以二级预防为目的降脂治疗现状。同时,揭示了血脂异常二级预防在实践过程中的挑战和问题,如对未达最佳血脂标准及依从性差等问题提出了可行性方案。